The pharmacotherapy of target symptoms associated with autistic disorder and other pervasive developmental disorders

Harvard Review of Psychiatry

Volumn 8, Issue 2, 2000, Pages 45-63

  Posey, David J ^a   McDougle, Christopher J ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RILEY HOSPITAL FOR CHILDREN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUSPIRONE; CITALOPRAM; CLOMIPRAMINE; CLONIDINE; CLOZAPINE; FENFLURAMINE; FLUOXETINE; FLUVOXAMINE; GUANFACINE; HALOPERIDOL; LITHIUM; NALTREXONE; OLANZAPINE; PAROXETINE; PIMOZIDE; PSYCHOSTIMULANT AGENT; QUETIAPINE; RISPERIDONE; SECRETIN; SEROTONIN UPTAKE INHIBITOR;

AUTISM; CHILD; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVELOPMENTAL DISORDER; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG TOLERABILITY; DYSKINESIA; HUMAN; HYPERACTIVITY; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEROTONIN SYNDROME;

EID: 0033917855     PISSN: 10673229     EISSN: None     Source Type: Journal    
DOI: 10.1080/hrp_8.2.45     Document Type: Review

References (171)

1. Kanner L. Autistic disturbances of affective contact. Nerv Child 1943;2:217-50.
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington, DC: American Psychiatric Association, 1980.
3. Lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview - Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord 1994;24:659-85.
4. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994.
5. Bryson SE. Epidemiology of autism: overview and issues outstanding. In: Cohen DJ, Volkmar FR, eds. Handbook of autism and pervasive developmental disorders. 2nd ed. New York: Wiley, 1997:41-6.
6. Aman MG, Van Bourgondien ME, Wolford PL, Sarphare G. Psychotropic and anticonvulsant drugs in subjects with autism: prevalence and patterns of use. J Am Acad Child Adolesc Psychiatry 1995;34:1672-81.
7. Martin A, Scahill L, Klin A, Volkmar FR. Higher-functioning pervasive developmental disorders: rates and patterns of psychotropic drug use. J Am Acad Child Adolesc Psychiatry 1999;38:923-31.
8. nd ed. London: MacKeith, 1992.
9. Volkmar FR, Cohen DJ. Comorbid association of autism and schizophrenia. Am J Psychiatry 1991;148:1705-7.
10. Campbell M. Drug treatment of infantile autism: the past decade. In: Meltzer HY, ed. Psychopharmacology: the third generation of progress. New York: Raven, 1987:1225-31.
11. Bender L, Faretra G, Cobrinik L. LSD and UML treatment of hospitalized disturbed children. In: Wortis J, ed. Recent advances in biological psychiatry. New York: Plenum, 1963: 84-92.
12. Fish B, Campbell M, Shapiro T, Floyd A Jr. Schizophrenic children treated with methysergide (Sansert). Dis Nerv Syst 1969;30:534-40.
13. Ritvo ER, Yuwiler A, Geller E, Kales A, Rashkis S, Schicor A, et al. Effects of 1-dopa in autism. J Autism Child Schizophr 1971;1:190-205.
14. Campbell M, Small AM, Hollander CS, Korein J, Cohen IL, Kalmijn M, et al. A controlled crossover study of triiodothyronine in autistic children. J Autism Child Schizophr 1978;8: 371-81.
15. Sverd J, Kupietz SS, Winsberg BG, Hurwic MJ, Becker L. Effects of L-5-hydroxytryptophan in autistic children. J Autism Child Schizophr 1978;8:171-80.
16. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337: 581-8.
17. Schain RJ, Freedman DX. Studies on 5-hydroxyindole metabolism in autistic and other mentally retarded children. J Pediatr 1961;58:315-20.
18. nd ed. New York: Wiley, 1997:325-43.
19. Clineschmidt BV, Zacchei AG, Totaro JA, Pflueger AB, McGuffin JC, Wishousky TI. Fenfluramine and brain serotonin. Ann NY Acad Sci 1978;305:222-41.
20. Geller E, Ritvo ER, Freeman BJ, Yuwiler A. Preliminary observations on the effect of fenfluramine on blood serotonin and symptoms in three autistic boys. N Engl J Med 1982; 307:165-9.
21. Ritvo ER, Freeman BJ, Yuwiler A, Geller E, Schroth P, Yokota A, et al. Fennuramine treatment of autism: UCLA collaborative study of 81 patients at nine medical centers. Psychopharmacol Bull 1986;22:133-40.
22. Campbell M, Adams P, Small AM, Curren EL, Overall JE, Anderson LT, et al. Efficacy and safety of fenfluramine in autistic children. J Am Acad Child Adolesc Psychiatry 1988; 27:434-9.
23. Ekman G, Miranda-Linné F, Gillberg C, Garle M, Wetterberg L. Fenfluramine treatment of twenty children with autism. J Autism Dev Disord 1989;19:511-32.
24. Sherman J, Factor DC, Swinson R, Darjes RW. The effects of fenfluramine (hydrochloride) on the behaviors of fifteen autistic children. J Autism Dev Disord 1989;19:533-43.
25. Duker PC, Welles K, Seys D, Rensen H, Vis A, Van den Berg G. Effects of fenfluramine on communicative, stereotypic, and inappropriate behaviors of autistic-type mentally handicapped individuals. J Autism Dev Disord 1991;21:355-63.
26. Realmuto GM, Jensen J, Klykylo W, Piggott L, Stubbs G, Yuwiler A, et al. Untoward effects of fenfluramine in autistic children. J Clin Psychopharmacol 1986;6:350-5.
27. Varley CK, Holm VA. A two-year follow-up of autistic children treated with fenfluramine. J Am Acad Child Adolesc Psychiatry 1990;29:137-40.
28. Schuster CR, Lewis M, Seiden LS. Fenfluramine: neurotoxicity. Psychopharmacol Bull 1986;22:148-51.
29. Leventhal BL, Cook EH Jr, Morford M, Ravitz AJ, Heller W, Freedman DX. Clinical and neurochemical effects of fenfluramine in children with autism. J Neuropsychiatry Clin Neurosci 1993;5:307-15.
30. Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996;335:609-16.
31. Aman MG, Singh NN. Patterns of drug use, methodological considerations, measurement techniques, and future trends. In: Aman MG, Singh NN, eds. Psycho pharmacology and the developmental disabilities. New York: Springer, 1988:1-28.
32. Campbell M, Geller B, Cohen IL. Current status of drug research and treatment with autistic children. J Pediatr Psychol 1977;2:153-61.
33. Campbell M, Fish B, Shapiro T, Floyd AJr. Acute responses of schizophrenic children to a sedative and a "stimulating" neuroleptic: a pharmacologic yardstick. Curr Therap Res 1972;14:759-66.
34. Fish B, Shapiro T, Campbell M. Long-term prognosis and the response of schizophrenic children to drug therapy: a controlled study of trifluoperazine. Am J Psychiatry 1966;123: 32-9.
35. Wolpert A, Hagamen MB, Merlis S. A comparative study of thiothixene and trifluoperazine in childhood schizophrenia. Curr Therap Res 1967;9:482-5.
36. Campbell M, Fish B, Shapiro T, Floyd A Jr. Thiothixene in young disturbed children: a pilot study. Arch Gen Psychiatry 1970;23:70-2.
37. Waizer J, Polizos P, Hoffman SP, Engelhardt DM, Margolis RA. A single-blind evaluation of thiothixene with outpatient schizophrenic children. J Autism Child Schizophr 1972;2: 378-86.
38. Faretra G, Dooher L, Dowling J. Comparison of haloperidol and fluphenazine in disturbed children. Am J Psychiatry 1970;126:1670-3.
39. Engelhardt DM, Polizos P, Waizer J, Hoffman SP A double-blind comparison of fluphenazine and haloperidol in outpatient schizophrenic children. J Autism Child Schizophr 1973; 3:128-37.
40. Campbell M, Fish B, Shapiro T, Floyd A Jr. Study of molindone in disturbed preschool children. Curr Therap Res 1971; 13:28-33.
41. Campbell M, Anderson LT, Meier M, Cohen IL, Small AM, Samit C, et al. A comparison of haloperidol and behavior therapy and their interaction in autistic children. J Am Acad Child Psychiatry 1978;17:640-55.
42. Fish B. Children's Psychiatric Rating Scale (scoring). Psychopharmacol Bull 1985;21:753-64.
43. Cohen IL, Campbell M, Posner D, Small AM, Triebel D, Anderson LT. Behavioral effects of haloperidol in young autistic children: an objective analysis using a within-subjects reversal design. J Am Acad Child Adolesc Psychiatry 1980;19: 665-77.
44. Anderson LT, Campbell M, Grega DM, Perry R, Small AM, Green WH. Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. Am J Psychiatry 1984;141:1195-202.
45. Guy W. ECDEU assessment manual for psychopharmacology. Rockville, Maryland: Department of Health, Education, and Welfare, National Institute of Mental Health, 1976.
46. Anderson LT, Campbell M, Adams P, Small AM, Perry R, Shell J. The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. J Autism Dev Disord 1989;19:227-39.
47. Conners CK. Conners Rating Scales manual. North Tonowanda, New York: Multi-Health Systems, 1989.
48. Perry R, Campbell M, Adams P, Lynch N, Spencer EK, Curren EL, et al. Long-term efficacy of haloperidol in autistic children: continuous versus discontinuous drug administration. J Am Acad Child Adolesc Psychiatry 1989;28:87-92.
49. Campbell M, Armenteros JL, Malone RP, Adams PB, Eisenberg ZW, Overall JE. Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. J Am Acad Child Adolesc Psychiatry 1997;36:835-43.
50. Armenteros JL, Adams PB, Campbell M, Eisenberg ZW. Haloperidol-related dyskinesias and pre- and perinatal complications in autistic children. Psychopharmacol Bull 1995;31: 363-9.
51. Naruse H, Nagahata M, Nakane Y, Shirahashi K, Takesada M, Yamazaki K. A multi-center double-blind trial of pimozide (Orap), haloperidol and placebo in children with behavioral disorders, using crossover design. Acta Paedopsychiatr 1982; 48:173-84.
52. Ernst M, Magee HJ, Gonzalez NM, Locascio JJ, Rosenberg CR, Campbell M. Pimozide in autistic children. Psychopharmacol Bull 1992;28:187-91.
53. McDougle CJ, Scahill L, McCracken JT, Aman MG, Tierney E, Arnold LE, et al. Research Units on Pediatric Psychopharmacology (RUPP) - Autism Network: background and rationale for an initial controlled study of risperidone. Child Adolesc Psychiatry Clin N Am 2000;9:201-24.
54. Zuddas A, Ledda MG, Fratta A, Muglia P, Cianchetti C. Clinical effects of clozapine on autistic disorder [Letter]. Am J Psychiatry 1996;153:738.
55. Vanden Borre R, Vermote R, Buttiëns M, Thiry P, Dierick G, Geutjens J, et al. Risperidone as add-on therapy in behavioural disturbances in mental retardation: a double-blind placebo-controlled cross-over study. Acta Psychiatr Scand 1993;87:167-71.
56. Lott RS, Kerrick JM, Cohen SA. Clinical and economic aspects of risperidone treatment in adults with mental retardation and behavioral disturbance. Psychopharmacol Bull 1996; 32:721-9.
57. Demb HB. Risperidone in young children with pervasive developmental disorders and other developmental disabilities [Letter]. J Child Adolesc Psychopharmacol 1996;6:79-80.
58. Simeon JG, Carrey NJ, Wiggins DM, Milin RP, Hosenbocus SN. Risperidone effects in treatment-resistant adolescents: preliminary case reports. J Child Adolesc Psychopharmacol 1995;5:69-79.
59. Fisman S, Steele M. Use of risperidone in pervasive developmental disorders: a case series. J Child Adolesc Psychopharmacol 1996;6:177-90.
60. Purdon SE, Lit W, Labelle A, Jones BDW. Risperidone in the treatment of pervasive developmental disorder. Can J Psychiatry 1994;39:400-5.
61. McDougle CJ, Brodkin ES, Yeung PP, Naylor ST, Cohen DJ, Price LH. Risperidone in adults with autism or pervasive developmental disorder. J ChildAdolesc Psychopharmacol 1995; 5:273-82.
62. Hardan A, Johnson K, Johnson C, Hrecznyj B. Case study: risperidone treatment of children and adolescents with developmental disorders. J Am Acad Child Adolesc Psychiatry 1996;35:1551-6.
63. Findling RL, Maxwell K, Wiznitzer M. An open clinical trial of risperidone monotherapy in young children with autistic disorder. Psychopharmacol Bull 1997;33:155-9.
64. Horrigan JP, Barnhill LJ. Risperidone and explosive aggressive autism. J Autism Dev Disord 1997;27:313-23.
65. Perry R, Pataki C, Munoz-Silva DM, Armenteros J, Silva RR. Risperidone in children and adolescents with pervasive developmental disorder: pilot trial and follow-up. J Child Adolesc Psychopharmacol 1997;7:167-79.
66. McDougle CJ, Holmes JP, Bronson MR, Anderson GM, Volkmar FR, Price LH, et al. Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective, open-label study. J Am Acad Child Adolesc Psychiatry 1997;36:685-93.
67. Nicolson R, Awad G, Sloman L. An open trial of risperidone in young autistic children. J Am Acad Child Adolesc Psychiatry 1998;37:372-6.
68. Overall JE, Campbell M. Behavioral assessment of psychopathology in children: infantile autism. J Clin Psychol 1988; 44:708-16.
69. Posey DJ, Walsh KH, Wilson GA, McDougle CJ. Risperidone in the treatment of two very young children with autism. J Child Adolesc Psychopharmacol 1999;9:273-6.
70. McDougle CJ, Holmes JP, Carlson DC, Pelton GH, Cohen DJ, Price LH. A double-blind placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry 1998;55: 633-41.
71. Horrigan JP, Barnhill LJ, Courvoisie HE. Olanzapine in PDD [Letter]. J Am Acad Child Adolesc Psychiatry 1997;36: 1166-7.
72. Rubin M. Use of atypical antipsychotics in children with mental retardation, autism, and other developmental disabilities. Psychiatr Ann 1997;27:219-21.
73. Malek-Ahmadi P, Simonds JF. Olanzapine for autistic disorder with hyperactivity [Letter]. J Am Acad Child Adolesc Psychiatry 1998;37:902.
74. Potenza MN, Holmes JP, Kanes SJ, McDougle CJ. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J Clin Psychopharmacol 1999;19:37-44.
75. Martin A, Koenig K, Scahill L, Bregman J. Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol 1999;9: 99-107.
76. Leonard HL, Swedo SE, Rapoport JL, Koby EV, Lenane MC, Cheslow DL, et al. Treatment of obsessive-compulsive disorder with clomipramine and desipramine in children and adolescents: a double-blind crossover comparison. Arch Gen Psychiatry 1989;46:1088-92.
77. McDougle CJ, Kresch LE, Goodman WK, Naylor ST, Volkmar FR, Cohen DJ, et al. A case-controlled study of repetitive thoughts and behavior in adults with autistic disorder and obsessive-compulsive disorder. Am J Psychiatry 1995;152: 772-7.
78. Gordon CT, State RC, Nelson JE, Hamburger SD, Rapoport JL. A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry 1993;50:441-7.
79. McDougle CJ, Price LH, Volkmar FR, Goodman WK, Ward-O'Brien D, Nielsen J, et al. Clomipramine in autism: preliminary evidence of efficacy. J Am Acad Child Adolesc Psychiatry 1992;31:746-50.
80. Garber HJ, McGonigle JJ, Slomka GT, Monteverde E. Clomipramine treatment of stereotypic behaviors and self-injury in patients with developmental disabilities. J Am Acad Child Adolesc Psychiatry 1992;31:1157-60.
81. Brasic JR, Barnett JY, Kaplan D, Sheitman BB, Aisemberg P, Lafargue RT, et al. Clomipramine ameliorates adventitious movements and compulsions in prepubertal boys with autistic disorder and severe mental retardation. Neurology 1994; 44:1309-12.
82. Brodkin ES, McDougle CJ, Naylor ST, Cohen DJ, Price LH. Clomipramine in adults with pervasive developmental disorders: a prospective open-label investigation. J Child Adolesc Psychopharmacol 1997;7:109-21.
83. Sanchez LE, Campbell M, Small AM, Cueva JE, Armenteros JL, Adams PB. A pilot study of clomipramine in young autistic children. J Am Acad Child Adolesc Psychiatry 1996;35: 537-44.
84. Brasic JR, Barnett JY, Sheitman BB, Lafargue RT, Kowalik S, Kaplan D, et al. Behavioral effects of clomipramine on prepubertal boys with autistic disorder and severe mental retardation. CNS Spectrums 1998;3:39-46.
85. Sloman L, Nicholson R. Medication in pervasive developmental disorder. Child Adolesc Psychopharmacol News 1999; 4:4-9.
86. McDougle CJ, Price LH, Goodman WK. Fluvoxamine treatment of coincident autistic disorder and obsessive-compulsive disorder: a case report. J Autism Dev Disord 1990; 20:537-43.
87. Harvey RJ, Cooray SE. The effective treatment of severe repetitive behaviour with fluvoxamine in a 20 year old autistic female. Int Clin Psychopharmacol 1995;10:201-3.
88. McDougle CJ, Naylor ST, Cohen DJ, Volkmar FR, Heninger GR, Price LH. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 1996;53:1001-8.
89. Freeman BJ, Ritvo ER, Yokota A, Ritvo A. A scale for rating symptoms of patients with the syndrome of autism in real life settings. J Am Acad Child Psychiatry 1986;25:130-6.
90. Mehlinger R, Scheftner WA, Poznanski E. Fluoxetine and autism [Letter]. J Am Acad Child Adolesc Psychiatry 1990;29: 985.
91. Ghaziuddin M, Tsai L, Ghaziuddin N. Fluoxetine in autism with depression [Letter]. J Am Acad Child Adolesc Psychiatry 1991;30:508-9.
92. Hamdan-Allen G. Trichotillomania in an autistic male. J Autism Dev Disord 1991;21:79-82.
93. Todd RD. Fluoxetine in autism [Letter]. Am J Psychiatry 1991;148:1089.
94. Koshes RJ. Use of fluoxetine for obsessive-compulsive behavior in adults with autism [Letter]. Am J Psychiatry 1997; 154:578.
95. Fatemi SH, Realmuto GM, Khan L, Thuras P. Fluoxetine in treatment of adolescent patients with autism: a longitudinal open trial. J Autism Dev Disord 1998;28:303-7.
96. Cook EH Jr, Rowlett R, Jaselskis C, Leventhal BL. Fluoxetine treatment of children and adults with autistic disorder and mental retardation. J Am Acad Child Adolesc Psychiatry 1992;31:739-45.
97. Branford D, Bhaumik S, Naik B. Selective serotonin reuptake inhibitors for the treatment of perseverative and maladaptive behaviours of people with intellectual disability. J Intellect Disabil Res 1998;42:301-6.
98. DeLong GR, Teague LA, McSwain KM. Effects of fluoxetine treatment in young children with idiopathic autism. Dev Med Child Neurol 1998;40:551-62.
99. Damore J, Stine J, Brody L. Medication-induced hypomania in Asperger's disorder [Letter]. J Am Acad Child Adolesc Psychiatry 1998;37:248-9.
100. Buck OD. Sertraline for reduction of violent behavior [Letter]. Am J Psychiatry 1995;152:953.
101. Ozbayrak KR. Sertraline in PDD [Letter]. J Am Acad Child Adolesc Psychiatry 1997;36:7-8.
102. Hellings JA, Kelley LA, Gabrielli WF, Kilgore E, Shah P Sertraline response in adults with mental retardation and autistic disorder. J Clin Psychiatry 1996;57:333-6.
103. Steingard RJ, Zimnitzky B, DeMaso DR, Bauman ML, Bucci JP. Sertraline treatment of transition-associated anxiety and agitation in children with autistic disorder. J Child Adolesc Psychopharmacol 1997;7:9-15.
104. McDougle CJ, Brodkin ES, Naylor ST, Carlson DC, Cohen DJ, Price LH. Sertraline in adults with pervasive developmental disorders: a prospective open-label investigation. J Clin Psychopharmacol 1998;18:62-6.
105. Snead RW, Boon F, Presberg J. Paroxetine for self-injurious behavior [Letter]. J Am Acad Child Adolesc Psychiatry 1994; 33:909-10.
106. Posey DJ, Litwiller M, Koburn A, McDougle CJ. Paroxetine in autism [Letter]. J Am Acad Child Adolesc Psychiatry 1999; 38:111-2.
107. Davanzo PA, Belin TR, Widawski MH, King BH. Paroxetine treatment of aggression and self-injury in persons with mental retardation. Am J Ment Retard 1998;102:427-37.
108. Campbell M, Fish B, Shapiro T, Floyd A Jr. Imipramine in preschool autistic and schizophrenic children. J Autism Child Schizophr 1971;1:267-82.
109. Gedye A. Trazodone reduced aggressive and self-injurious movements in a mentally handicapped male patient with autism [Letter]. J Clin Psychopharmacol 1991;11:275-6.
110. Panksepp J, Sahley TL. Possible brain opioid involvement in disrupted social intent and language development of autism. In: Schopler E, Mesibov GB, eds. Neurobiological issues in autism. New York: Plenum, 1987:357-72.
111. Campbell M, Overall JE, Small AM, Sokol MS, Spencer EK, Adams P, et al. Naltrexone in autistic children: an acute open dose range tolerance trial. J Am Acad Child Adolesc Psychiatry 1989;28:200-6.
112. Panksepp J, Lensing P A synopsis of an open-trial of naltrexone treatment of autism with four children. J Autism Dev Disord 1991;21:243-9.
113. Scifo R, Batticane N, Quattropani MC, Spoto G, Marchetti B. A double-blind trial with naltrexone in autism. Brain Dysfunct 1991;4:301-7.
114. Barthelemy C, Adrien JL, Tanguay P, Garreau B, Fermanian J, Roux S, et al. The Behavioral Summarized Evaluation: validity and reliability of a scale for the assessment of autistic behaviors. J Autism Dev Disord 1990;20:189-204.
115. Leboyer M, Bouvard MP, Launay JM, Tabuteau F, Waller D, Dugas M, et al. A double-blind study of naltrexone in infantile autism. J Autism Dev Disord 1992;22:309-19.
116. Campbell M, Anderson LT, Small AM, Adams P, Gonzalez NM, Ernst M. Naltrexone in autistic children: behavioral symptoms and attentional learning. J Am Acad Child Adolesc Psychiatry 1993;32:1283-91.
117. Bouvard MP, Leboyer M, Launay JM, Recasens C, Plumet MH, Waller-Perotte D, et al. Low-dose naltrexone effects on plasma chemistries and clinical symptoms in autism: a double-blind, placebo-controlled study. Psychiatry Res 1995; 58:191-201.
118. Willemsen-Swinkels SHN, Buitelaar JK, Nijhof GJ, Van Engeland H. Failure of naltrexone hydrochloride to reduce self-injurious and autistic behavior in mentally retarded adults: double-blind placebo-controlled studies. Arch Gen Psychiatry 1995;52:766-73.
119. Willemsen-Swinkels SHN, Buitelaar JK, Weijnen FG, Van Engeland H. Placebo-controlled acute dosage naltrexone study in young autistic children. Psychiatry Res 1995;58: 203-15.
120. Willemsen-Swinkels SHN, Buitelaar JK, Van Engeland H. The effects of chronic naltrexone treatment in young autistic children: a double-blind placebo-controlled crossover study. Biol Psychiatry 1996;39:1023-31.
121. Kolmen BK, Feldman HM, Handen BL, Janosky JE. Naltrexone in young autistic children: a double-blind placebo-controlled crossover study. J Am Acad Child Adolesc Psychiatry 1995;34:223-31.
122. Kolmen BK, Feldman HM, Handen BL, Janosky JE. Naltrexone in young autistic children: replication study and learning measures. J Am Acad Child Adolesc Psychiatry 1997;36:1570-8.
123. Feldman HM, Kolmen BK, Gonzaga AM. Naltrexone and communication skills in young children with autism. J Am Acad Child Adolesc Psychiatry 1999;38:587-93.
124. Hunt RD, Minderaa RB, Cohen DJ. Clonidine benefits children with attention deficit disorder and hyperactivity: report of a double-blind placebo-crossover therapeutic trial. J Am Acad Child Psychiatry 1985;24:617-29.
125. Leckman JF, Hardin MT, Riddle MA, Stevenson J, Ort SI, Cohen DJ. Clonidine treatment of Gilles de la Tourette's syndrome. Arch Gen Psychiatry 1991;48:324-8.
126. Gold MS, Pottash AL, Sweeney DR, Kleber HD. Efficacy of clonidine in opiate withdrawal: a study of thirty patients. Drug Alcohol Depend 1980;6:201-8.
127. Ghaziuddin M, Tsai L, Ghaziuddin N. Clonidine for autism. J Child Adolesc Psychopharmacol 1992;2:239-40.
128. Koshes RJ, Rock NL. Use of clonidine for behavioral control in an adult patient with autism [Letter]. Am J Psychiatry 1994;151:1714.
129. Jaselskis CA, Cook EH Jr, Fletcher KE, Leventhal BL. Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin Psychopharmacol 1992;12:322-7.
130. Aman MG, Singh NN, Stewart AW, Field CJ. The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic 1985;89:485-91.
131. Sanchez LE, Adams PB, Uysal S, Hallin A, Campbell M, Small AM. A comparison of live and videotape ratings: clomipramine and haloperidol in autism. Psychopharmacol Bull 1995;31:371-8.
132. Fankhauser MP, Karumanchi VC, German ML, Yates A, Karumanchi SD. A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. J Clin Psychiatry 1992;53:77-82.
133. Kofoed L, Tadepalli G, Oesterheld JR, Awadallah S, Shapiro R. Case series: clonidine has no systematic effects on PR or QTc intervals in children. J Am Acad Child Adolesc Psychiatry 1999;38:1193-6.
134. Swanson JM, Flockhart D, Udrea D, Cantwell D, Connor D, Williams L. Clonidine in the treatment of ADHD: questions about safety and efficacy. J Child Adolesc Psychopharmacol 1995;5:301-4.
135. Arnsten AFT, Cai JX, Goldman-Rakic PS. The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: evidence for alpha-2 receptor subtypes. J Neurosci 1988;8:4287-98.
136. Balldin J, Berggren U, Eriksson E, Lindstedt G, Sundkler A. Guanfacine as an alpha-2-agonist inducer of growth hormone secretion - a comparison with clonidine. Psychoneuroendocrinology 1993;18:45-55.
137. Hunt RD, Arnsten AFT, Asbell MD. An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1995;34:50-4.
138. Chappell PB, Riddle MA, Scahill L, Lynch KA, Schultz R, Arnsten A, et al. Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette's syndrome: preliminary clinical experience. J Am Acad Child Adolesc Psychiatry 1995;34:1140-6.
139. Campbell M, Fish B, David R, Shapiro T, Collins P, Koh C. Response to triiodothyronine and dextroamphetamine: a study of preschool schizophrenic children. J Autism Child Schizophr 1972;2:343-58.
140. Campbell M, Small AM, Collins PJ, Friedman E, David R, Genieser N. Levodopa and levoamphetamine: a crossover study in young schizophrenic children. Curr Therap Res 1976;19:70-86.
141. Geller B, Guttmacher LB, Bleeg M. Coexistence of childhood onset pervasive developmental disorder and attention deficit disorder with hyperactivity. Am J Psychiatry 1981;138: 388-9.
142. Vitriol C, Farber B. Stimulant medication in certain childhood disorders [Letter]. Am J Psychiatry 1981;138:1517-8.
143. Hoshino Y, Kumashiro H, Kaneko M, Takahashi Y. The effects of methylphenidate on early infantile autism and its relation to serum serotonin levels. Folia Psychiatr Neurol Jap 1977;31:605-14.
144. Strayhorn JM, Rapp N, Donina W, Strain PS. Randomized trial of methylphenidate for an autistic child. J Am Acad Child Adolesc Psychiatry 1988;27:244-7.
145. Realmuto GM, August GJ, Garfinkel BD. Clinical effect of buspirone in autistic children. J Clin Psychopharmacol 1989; 9:122-5.
146. Birmaher B, Quintana H, Greenhill LL. Methylphenidate treatment of hyperactive autistic children. J Am Acad Child Adolesc Psychiatry 1988;27:248-51.
147. Quintana H, Birmaher B, Stedge D, Lennon S, Freed J, Bridge J, et al. Use of methylphenidate in the treatment of children with autistic disorder. J Autism Dev Disord 1995; 25:283-94.
148. Ratey JJ, Sovner R, Mikkelsen E, Chmielinski HE. Buspirone therapy for maladaptive behavior and anxiety in developmentally disabled persons. J Clin Psychiatry 1989;50: 382-4.
149. Ricketts RW, Goza AB, Ellis CR, Singh YN, Chambers S, Singh NN, et al. Clinical effects of buspirone on intractable self-injury in adults with mental retardation. J Am Acad Child Adolesc Psychiatry 1994;33:270-6.
150. Hillbrand M, Scott K. The use of buspirone with aggressive behavior [Letter]. J Autism Dev Disord 1995;25:663-4.
151. McCormick LH. Treatment with buspirone in a patient with autism. Arch Fam Med 1997;6:368-70.
152. King BH, Davanzo P. Buspirone treatment of aggression and self-injury in autistic and nonautistic persons with severe mental retardation. Dev Brain Dysfunct 1996;9:22-31.
153. Buitelaar JK, Van der Gaag RJ, Van der Hoeven J. Buspirone in the management of anxiety and irritability in children with pervasive developmental disorders: results of an open-label study. J Clin Psychiatry 1998;59:56-9.
154. Campbell M, Fish B, Korein J, Shapiro T, Collins P, Koh C. Lithium and chlorpromazine: a controlled crossover study of hyperactive severely disturbed young children. J Autism Child Schizophr 1972;2:234-63.
155. Kerbeshian J, Burd L, Fisher W. Lithium carbonate in the treatment of two patients with infantile autism and atypical bipolar symptomatology. J Clin Psychopharmacol 1987;7: 401-5.
156. Steingard R, Biederman J. Lithium-responsive manic-like symptoms in two individuals with autism and mental retardation. J Am Acad Child Adolesc Psychiatry 1987;26:932-5.
157. Epperson CN, McDougle CJ, Anand A, Marek GJ, Naylor ST, Volkmar FR, et al. Lithium augmentation of fluvoxamine in autistic disorder: a case report. J Child Adolesc Psychopharmacol 1994;4:201-7.
158. Kastner T, Finesmith R, Walsh K. Long-term administration of valproic acid in the treatment of affective symptoms in people with mental retardation. J Clin Psychopharmacol 1993;13:448-51.
159. Kafantaris V, Campbell M, Padron-Gayol MV, Small AM, Locascio JJ, Rosenberg CR. Carbamazepine in hospitalized aggressive conduct disorder children: an open pilot study. Psychopharmacol Bull 1992;28:193-9.
160. Silva RR, Munoz D, Alpert M. Carbamazepine use in children and adolescents with features of attention-deficit hyperactivity disorder: a meta-analysis. J AmAcad Child Adolesc Psychiatry 1996;35:352-8.
161. Uvebrant P, Bauzienè R. Intractable epilepsy in children: the efficacy of lamotrigine treatment, including non-seizure-related benefits. Neuropediatrics 1994;25:284-9.
162. Ratey JJ, Mikkelsen EJ, Smith GB, Upadhyaya A, Zuckerman HS, Martell D, et al. β-blockers in the severely and profoundly mentally retarded. J Clin Psychopharmacol 1986;6: 103-7.
163. Ratey JJ, Mikkelsen E, Sorgi P, Zuckerman HS, Polakoff S, Bemporad J, et al. Autism: the treatment of aggressive behaviors. J Clin Psychopharmacol 1987;7:35-41.
164. Ratey JJ, Bemporad J, Sorgi P, Bick P, Polakoff S, O'Driscoll G, et al. Open trial effects of beta-blockers on speech and social behaviors in 8 autistic adults. J Autism Dev Disord 1987;17:439-46.
165. Horvath K, Stefanatos G, Sokolski KN, Wachtel R, Nabors L, Tildon JT. Improved social and language skills after secretin administration in patients with autistic spectrum disorders. J Assoc Acad Minor Phys 1998;9:9-15.
166. Owley T, Steele E, Corsello C, Risi S, McKaig K, Lord C, et al. A double-blind, placebo-controlled trial of secretin for the treatment of autistic disorder. Medscape Gen Med 1999; 1(10) [Available at: http://www.medscape.com/medscape/General-Medicine/journal/1999/v01.n10/mgm1006. owle/mgm1006. owle-01.html].
167. Lord C, Rutter M, DiLavore P, Risi S. The ADOS-G (Autism Diagnostic Observation Schedule - Generic). Santa Monica, California: Western Psychological Services [In press].
168. Gilliam J. The Gilliam Autism Rating Scale. Austin, Texas: Pro-Ed, 1995.
169. Sandler AD, Sutton KA, DeWeese J, Girardi MA, Sheppard V, Bodfish JW. Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder. N Engl J Med 1999;341:1801-6.
170. nd ed. Examiner's manual. Austin, Texas: Pro-Ed, 1980.
171. Sparrow SS, Balla DA, Cicchetti DV. Vineland Adaptive Behavior Scales (a revision of the Vineland Social Maturity Scale by Edgar A Doll). Circle Pines, Minnesota: American Guidance Service, 1984.